25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

7148 (Duopharma Biotech Bhd) Stock Analysis
Buy, Hold or Sell?

Let's analyze Duopharma Biotech Bhd together

I guess you are interested in Duopharma Biotech Bhd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Duopharma Biotech Bhd’s Financial Insights
  • 📈 Technical Analysis (TA) – Duopharma Biotech Bhd’s Price Targets

I'm going to help you getting a better view of Duopharma Biotech Bhd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Duopharma Biotech Bhd

I send you an email if I find something interesting about Duopharma Biotech Bhd.

1. Quick Overview

1.1. Quick analysis of Duopharma Biotech Bhd (30 sec.)










1.2. What can you expect buying and holding a share of Duopharma Biotech Bhd? (30 sec.)

How much money do you get?

How much money do you get?
RM0.01
When do you have the money?
1 year
How often do you get paid?
47.5%

What is your share worth?

Current worth
RM0.74
Expected worth in 1 year
RM0.77
How sure are you?
85.0%

+ What do you gain per year?

Total Gains per Share
RM0.06
Return On Investment
4.5%

For what price can you sell your share?

Current Price per Share
RM1.37
Expected price per share
RM1.3 - RM1.46
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Duopharma Biotech Bhd (5 min.)




Live pricePrice per Share (EOD)
RM1.37
Intrinsic Value Per Share
RM0.11 - RM1.89
Total Value Per Share
RM0.85 - RM2.63

2.2. Growth of Duopharma Biotech Bhd (5 min.)




Is Duopharma Biotech Bhd growing?

Current yearPrevious yearGrowGrow %
How rich?$168.8m$161.1m$5.5m3.3%

How much money is Duopharma Biotech Bhd making?

Current yearPrevious yearGrowGrow %
Making money$4.3m$2.6m$1.6m38.0%
Net Profit Margin8.2%6.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Duopharma Biotech Bhd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Duopharma Biotech Bhd?

Welcome investor! Duopharma Biotech Bhd's management wants to use your money to grow the business. In return you get a share of Duopharma Biotech Bhd.

First you should know what it really means to hold a share of Duopharma Biotech Bhd. And how you can make/lose money.

Speculation

The Price per Share of Duopharma Biotech Bhd is RM1.37. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Duopharma Biotech Bhd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Duopharma Biotech Bhd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is RM0.74. Based on the TTM, the Book Value Change Per Share is RM0.01 per quarter. Based on the YOY, the Book Value Change Per Share is RM0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is RM0.01 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Duopharma Biotech Bhd.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 RM% of Price per ShareRM% of Price per ShareRM% of Price per ShareRM% of Price per ShareRM% of Price per ShareRM% of Price per Share
Usd Eps0.010.5%0.000.3%0.000.2%0.000.3%0.000.3%0.000.2%
Usd Book Value Change Per Share0.000.0%0.000.1%0.000.1%0.000.1%0.000.2%0.000.2%
Usd Dividend Per Share0.000.3%0.000.1%0.000.1%0.000.1%0.000.1%0.000.1%
Usd Total Gains Per Share0.010.4%0.000.3%0.000.2%0.000.2%0.000.3%0.000.3%
Usd Price Per Share0.28-0.30-0.29-0.31-0.41-0.44-
Price to Earnings Ratio11.26-17.58-27.91-21.49-27.11-39.45-
Price-to-Total Gains Ratio52.86-88.73-135.90-119.07-123.42-82.37-
Price to Book Ratio1.62-1.74-1.76-1.86-2.59-3.48-
Price-to-Total Gains Ratio52.86-88.73-135.90-119.07-123.42-82.37-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.324964
Number of shares3077
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (3077 shares)11.1811.28
Gains per Year (3077 shares)44.7245.13
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1222335192635
2444680385280
366681255878125
4889117077104170
510911421596130215
6131137260115155260
7153160305135181305
8175183350154207350
9197205395173233395
10219228440192259440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%12.00.00.0100.0%20.00.00.0100.0%40.00.00.0100.0%53.00.00.0100.0%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%16.04.00.080.0%31.09.00.077.5%41.012.00.077.4%
Dividend per Share2.00.02.050.0%9.00.03.075.0%14.00.06.070.0%19.00.021.047.5%22.00.031.041.5%
Total Gains per Share4.00.00.0100.0%12.00.00.0100.0%19.01.00.095.0%34.06.00.085.0%44.09.00.083.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Duopharma Biotech Bhd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0030.008-65%0.003-19%0.007-59%0.009-70%0.013-79%
Book Value Per Share--0.7400.731+1%0.706+5%0.705+5%0.680+9%0.582+27%
Current Ratio--3.8324.152-8%3.206+20%3.152+22%2.825+36%2.799+37%
Debt To Asset Ratio--0.4920.487+1%0.486+1%0.480+3%0.463+6%0.419+18%
Debt To Equity Ratio--0.9700.948+2%0.947+2%0.923+5%0.866+12%0.754+29%
Dividend Per Share--0.0200.007+167%0.007+194%0.006+243%0.007+204%0.004+372%
Enterprise Value--464057941.200739603635.780-37%779507599.840-40%818604514.433-43%1263349055.796-63%1480347921.018-69%
Eps--0.0270.019+40%0.012+126%0.017+61%0.017+59%0.014+92%
Ev To Sales Ratio--0.4420.866-49%1.123-61%1.109-60%1.962-77%3.166-86%
Free Cash Flow Per Share--0.0250.020+22%0.011+123%0.008+220%0.001+2249%-0.003+112%
Free Cash Flow To Equity Per Share--0.0250.014+84%0.029-13%0.012+113%0.008+206%0.011+123%
Gross Profit Margin--1.000-0.431+143%-1.387+239%-0.780+178%-0.617+162%-0.734+173%
Intrinsic Value_10Y_max--1.885----------
Intrinsic Value_10Y_min--0.113----------
Intrinsic Value_1Y_max--0.054----------
Intrinsic Value_1Y_min---0.008----------
Intrinsic Value_3Y_max--0.265----------
Intrinsic Value_3Y_min---0.008----------
Intrinsic Value_5Y_max--0.600----------
Intrinsic Value_5Y_min--0.011----------
Market Cap1317860561.920+12%1154330941.2001219261635.780-5%1192808099.840-3%1258540847.767-8%1665121655.796-31%1771656721.018-35%
Net Profit Margin--0.0980.082+20%0.064+51%0.083+18%0.092+6%0.094+4%
Operating Margin---0.096-100%0.110-100%0.114-100%0.127-100%0.131-100%
Operating Ratio--1.4981.034+45%0.895+67%0.932+61%0.901+66%0.887+69%
Pb Ratio1.852+12%1.6221.736-7%1.756-8%1.860-13%2.587-37%3.475-53%
Pe Ratio12.850+12%11.25517.578-36%27.908-60%21.491-48%27.113-58%39.452-71%
Price Per Share1.370+12%1.2001.268-5%1.240-3%1.308-8%1.731-31%1.842-35%
Price To Free Cash Flow Ratio13.707+12%12.006-1.312+111%9.679+24%-8.787+173%-8.608+172%-167.022+1491%
Price To Total Gains Ratio60.348+12%52.86088.731-40%135.903-61%119.071-56%123.419-57%82.374-36%
Quick Ratio--1.2002.405-50%2.241-46%1.957-39%1.748-31%1.761-32%
Return On Assets--0.0180.013+38%0.009+112%0.012+49%0.013+38%0.014+34%
Return On Equity--0.0360.026+39%0.017+116%0.023+54%0.025+46%0.024+51%
Total Gains Per Share--0.0230.015+48%0.010+124%0.012+83%0.015+47%0.017+30%
Usd Book Value--168827574.400166686607.200+1%161130553.000+5%160787324.600+5%155139319.820+9%132836536.450+27%
Usd Book Value Change Per Share--0.0010.002-65%0.001-19%0.002-59%0.002-70%0.003-79%
Usd Book Value Per Share--0.1760.173+1%0.168+5%0.167+5%0.161+9%0.138+27%
Usd Dividend Per Share--0.0050.002+167%0.002+194%0.001+243%0.002+204%0.001+372%
Usd Enterprise Value--110074543.653175433982.407-37%184899202.682-40%194172990.824-43%299666396.035-63%351138526.865-69%
Usd Eps--0.0060.005+40%0.003+126%0.004+61%0.004+59%0.003+92%
Usd Free Cash Flow--5701576.4004672602.800+22%2558795.000+123%1781589.433+220%242750.480+2249%-689315.060+112%
Usd Free Cash Flow Per Share--0.0060.005+22%0.003+123%0.002+220%0.000+2249%-0.001+112%
Usd Free Cash Flow To Equity Per Share--0.0060.003+84%0.007-13%0.003+113%0.002+206%0.003+123%
Usd Market Cap312596525.287+12%273807299.253289208860.007-5%282934081.282-3%298525889.090-8%394966856.755-31%420236974.225-35%
Usd Price Per Share0.325+12%0.2850.301-5%0.294-3%0.310-8%0.411-31%0.437-35%
Usd Profit--6081808.0004329315.100+40%2685697.000+126%3770511.433+61%3816239.640+59%3172312.800+92%
Usd Revenue--62321453.60052389474.500+19%41345146.000+51%45303934.933+38%41844938.260+49%34199851.800+82%
Usd Total Gains Per Share--0.0050.004+48%0.002+124%0.003+83%0.004+47%0.004+30%
 EOD+4 -4MRQTTM+23 -16YOY+22 -173Y+24 -155Y+24 -1510Y+24 -15

3.3 Fundamental Score

Let's check the fundamental score of Duopharma Biotech Bhd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1512.850
Price to Book Ratio (EOD)Between0-11.852
Net Profit Margin (MRQ)Greater than00.098
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.200
Current Ratio (MRQ)Greater than13.832
Debt to Asset Ratio (MRQ)Less than10.492
Debt to Equity Ratio (MRQ)Less than10.970
Return on Equity (MRQ)Greater than0.150.036
Return on Assets (MRQ)Greater than0.050.018
Total6/10 (60.0%)

3.4 Technical Score

Let's check the technical score of Duopharma Biotech Bhd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.609
Ma 20Greater thanMa 501.357
Ma 50Greater thanMa 1001.310
Ma 100Greater thanMa 2001.254
OpenGreater thanClose1.360
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Duopharma Biotech Bhd

Duopharma Biotech Berhad, an investment holding company, researches, develops, manufactures, distributes, and imports pharmaceutical products and medicines in Malaysia and internationally. The company offers consumer healthcare products, such as vitamins, minerals, and supplements, analgesics, eyecare, antacids, and skin care products; and generic drugs for various therapeutic classes, such as cardiovascular, dermatology, hormones, respiratory, sensory and nervous system, musculo-skeletal system, anti-infectives, and others. It also provides specialty pharmaceutical drugs for targeted conditions, biosimilar products, and medical devices and consumables to patients with conditions, including diabetes, cancer, cardiovascular, renal, and other diseases. The company's product portfolio includes covasc, crystorvas, and vytocor; lebreta, and krabeva; and unihepa, erysaa, bi-haemosol, and haemosol. In addition, it offers its products under the Champs, Flavettes, Eye Glo, Proviton, Naturalle, IRORO Nutreatment, and Uphamol brands. The company was formerly known as CCM Duopharma Biotech Berhad and changed its name to Duopharma Biotech Berhad in February 2019. The company was founded in 1978 and is based in Klang, Malaysia.

Fundamental data was last updated by Penke on 2025-06-28 07:57:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Duopharma Biotech Bhd earns for each RM1 of revenue.

  • Above 10% is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 9.8% means that RM0.10 for each RM1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Duopharma Biotech Bhd:

  • The MRQ is 9.8%. The company is making a profit. +1
  • The TTM is 8.2%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ9.8%TTM8.2%+1.6%
TTM8.2%YOY6.4%+1.7%
TTM8.2%5Y9.2%-1.0%
5Y9.2%10Y9.4%-0.2%
4.3.1.2. Return on Assets

Shows how efficient Duopharma Biotech Bhd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 1.8% Return on Assets means that Duopharma Biotech Bhd generated RM0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Duopharma Biotech Bhd:

  • The MRQ is 1.8%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.8%TTM1.3%+0.5%
TTM1.3%YOY0.9%+0.5%
TTM1.3%5Y1.3%+0.0%
5Y1.3%10Y1.4%0.0%
4.3.1.3. Return on Equity

Shows how efficient Duopharma Biotech Bhd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 3.6% Return on Equity means Duopharma Biotech Bhd generated RM0.04 for each RM1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Duopharma Biotech Bhd:

  • The MRQ is 3.6%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.6%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ3.6%TTM2.6%+1.0%
TTM2.6%YOY1.7%+0.9%
TTM2.6%5Y2.5%+0.1%
5Y2.5%10Y2.4%+0.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Duopharma Biotech Bhd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Duopharma Biotech Bhd is operating .

  • Measures how much profit Duopharma Biotech Bhd makes for each RM1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated RM0.00  for each RM1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Duopharma Biotech Bhd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM9.6%-9.6%
TTM9.6%YOY11.0%-1.4%
TTM9.6%5Y12.7%-3.1%
5Y12.7%10Y13.1%-0.4%
4.3.2.2. Operating Ratio

Measures how efficient Duopharma Biotech Bhd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.50 means that the operating costs are RM1.50 for each RM1 in net sales.

Let's take a look of the Operating Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 1.498. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.034. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.498TTM1.034+0.464
TTM1.034YOY0.895+0.139
TTM1.0345Y0.901+0.133
5Y0.90110Y0.887+0.014
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Duopharma Biotech Bhd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Duopharma Biotech Bhd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.83 means the company has RM3.83 in assets for each RM1 in short-term debts.

Let's take a look of the Current Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 3.832. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.152. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.832TTM4.152-0.320
TTM4.152YOY3.206+0.946
TTM4.1525Y2.825+1.328
5Y2.82510Y2.799+0.026
4.4.3.2. Quick Ratio

Measures if Duopharma Biotech Bhd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.20 means the company can pay off RM1.20 for each RM1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 1.200. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 2.405. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.200TTM2.405-1.204
TTM2.405YOY2.241+0.163
TTM2.4055Y1.748+0.656
5Y1.74810Y1.761-0.013
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Duopharma Biotech Bhd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Duopharma Biotech Bhd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Duopharma Biotech Bhd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.49 means that Duopharma Biotech Bhd assets are financed with 49.2% credit (debt) and the remaining percentage (100% - 49.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 0.492. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.487. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.492TTM0.487+0.006
TTM0.487YOY0.486+0.001
TTM0.4875Y0.463+0.024
5Y0.46310Y0.419+0.044
4.5.4.2. Debt to Equity Ratio

Measures if Duopharma Biotech Bhd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 97.0% means that company has RM0.97 debt for each RM1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Duopharma Biotech Bhd:

  • The MRQ is 0.970. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.948. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.970TTM0.948+0.022
TTM0.948YOY0.947+0.001
TTM0.9485Y0.866+0.081
5Y0.86610Y0.754+0.113
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every RM1 in earnings Duopharma Biotech Bhd generates.

  • Above 15 is considered overpriced but always compare Duopharma Biotech Bhd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 11.26 means the investor is paying RM11.26 for every RM1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Duopharma Biotech Bhd:

  • The EOD is 12.850. Based on the earnings, the company is underpriced. +1
  • The MRQ is 11.255. Based on the earnings, the company is underpriced. +1
  • The TTM is 17.578. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD12.850MRQ11.255+1.594
MRQ11.255TTM17.578-6.323
TTM17.578YOY27.908-10.329
TTM17.5785Y27.113-9.534
5Y27.11310Y39.452-12.339
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Duopharma Biotech Bhd:

  • The EOD is 13.707. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 12.006. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -1.312. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD13.707MRQ12.006+1.701
MRQ12.006TTM-1.312+13.318
TTM-1.312YOY9.679-10.990
TTM-1.3125Y-8.608+7.296
5Y-8.60810Y-167.022+158.414
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Duopharma Biotech Bhd is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Duopharma Biotech Bhd:

  • The EOD is 1.852. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.622. Based on the equity, the company is underpriced. +1
  • The TTM is 1.736. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.852MRQ1.622+0.230
MRQ1.622TTM1.736-0.114
TTM1.736YOY1.756-0.020
TTM1.7365Y2.587-0.851
5Y2.58710Y3.475-0.888
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in MYR. All numbers in thousands.

Summary
Total Assets1,402,025
Total Liabilities690,273
Total Stockholder Equity711,752
 As reported
Total Liabilities 690,273
Total Stockholder Equity+ 711,752
Total Assets = 1,402,025

Assets

Total Assets1,402,025
Total Current Assets760,076
Long-term Assets641,949
Total Current Assets
Cash And Cash Equivalents 258,847
Net Receivables 238,073
Inventory 244,045
Total Current Assets  (as reported)760,076
Total Current Assets  (calculated)740,965
+/- 19,111
Long-term Assets
Property Plant Equipment 563,357
Long-term Assets  (as reported)641,949
Long-term Assets  (calculated)563,357
+/- 78,592

Liabilities & Shareholders' Equity

Total Current Liabilities198,330
Long-term Liabilities491,943
Total Stockholder Equity711,752
Total Current Liabilities
Short Long Term Debt 40,581
Accounts payable 156,060
Total Current Liabilities  (as reported)198,330
Total Current Liabilities  (calculated)196,641
+/- 1,689
Long-term Liabilities
Long term Debt 460,320
Long-term Liabilities  (as reported)491,943
Long-term Liabilities  (calculated)460,320
+/- 31,623
Total Stockholder Equity
Retained Earnings 361,177
Total Stockholder Equity (as reported)711,752
Total Stockholder Equity (calculated)361,177
+/- 350,575
Other
Capital Stock432,466
Common Stock Shares Outstanding 961,942
Net Debt 242,054
Net Invested Capital 1,212,653
Net Working Capital 561,746



6.2. Balance Sheets Structured

Currency in MYR. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-31
> Total Assets 
201,782
197,931
195,539
198,030
203,809
213,667
217,013
205,652
225,811
218,296
227,022
222,477
239,183
541,930
660,529
633,446
642,424
632,404
639,069
661,463
694,557
689,041
711,265
705,240
745,045
802,944
835,128
836,378
875,922
910,726
907,542
919,801
959,496
1,007,333
997,257
1,058,432
1,105,955
1,096,800
1,179,185
1,164,131
1,203,979
1,204,377
1,216,686
1,221,919
1,242,074
1,248,792
1,383,502
1,345,135
1,313,255
1,343,710
1,352,933
1,376,998
1,402,025
1,402,0251,376,9981,352,9331,343,7101,313,2551,345,1351,383,5021,248,7921,242,0741,221,9191,216,6861,204,3771,203,9791,164,1311,179,1851,096,8001,105,9551,058,432997,2571,007,333959,496919,801907,542910,726875,922836,378835,128802,944745,045705,240711,265689,041694,557661,463639,069632,404642,424633,446660,529541,930239,183222,477227,022218,296225,811205,652217,013213,667203,809198,030195,539197,931201,782
   > Total Current Assets 
100,895
94,283
93,140
92,620
100,271
104,410
105,821
94,188
112,077
104,145
113,226
106,854
119,497
268,193
383,497
354,346
362,345
351,875
358,035
366,182
387,552
378,126
378,229
356,619
385,017
391,482
395,610
367,330
396,476
431,540
429,803
417,205
452,220
486,727
444,683
459,693
510,357
458,509
536,337
494,796
526,260
529,583
544,339
541,487
565,411
575,987
716,548
677,065
656,529
697,195
725,294
727,051
760,076
760,076727,051725,294697,195656,529677,065716,548575,987565,411541,487544,339529,583526,260494,796536,337458,509510,357459,693444,683486,727452,220417,205429,803431,540396,476367,330395,610391,482385,017356,619378,229378,126387,552366,182358,035351,875362,345354,346383,497268,193119,497106,854113,226104,145112,07794,188105,821104,410100,27192,62093,14094,283100,895
       Cash And Cash Equivalents 
11,024
1,846
4,777
14,139
18,443
20,311
19,580
18,879
18,028
6,805
15,859
18,303
30,485
31,320
142,797
143,510
146,900
122,574
132,326
114,814
111,651
82,917
86,800
96,021
76,749
77,211
94,073
98,254
73,967
96,170
92,123
120,669
126,726
163,674
129,965
158,029
149,270
109,073
109,696
137,980
152,548
143,600
142,385
157,637
127,880
135,565
281,884
270,502
232,321
221,162
260,423
264,545
258,847
258,847264,545260,423221,162232,321270,502281,884135,565127,880157,637142,385143,600152,548137,980109,696109,073149,270158,029129,965163,674126,726120,66992,12396,17073,96798,25494,07377,21176,74996,02186,80082,917111,651114,814132,326122,574146,900143,510142,79731,32030,48518,30315,8596,80518,02818,87919,58020,31118,44314,1394,7771,84611,024
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1,100
-1,100
-1,100
-1,050
-1,050
-1,050
-1,050
-1,050
-1,050
-1,050
-1,050
161,795
0
0
0
0
0
00000161,795-1,050-1,050-1,050-1,050-1,050-1,050-1,050-1,050-1,100-1,100-1,100000000000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
121,000
120,000
102,000
99,000
108,309
102,992
90,300
131,833
147,448
137,711
103,102
176,874
176,676
162,039
122,484
178,065
183,109
179,024
130,789
195,192
174,261
161,848
124,774
185,162
164,533
187,710
132,720
170,559
179,067
188,469
142,152
192,769
186,236
182,271
161,419
180,443
249,181
223,672
195,767
238,073
238,073195,767223,672249,181180,443161,419182,271186,236192,769142,152188,469179,067170,559132,720187,710164,533185,162124,774161,848174,261195,192130,789179,024183,109178,065122,484162,039176,676176,874103,102137,711147,448131,83390,300102,992108,30999,000102,000120,000121,0000000000000000
       Inventory 
43,500
46,797
47,558
41,383
39,614
39,783
36,758
36,331
52,961
55,682
52,077
44,644
45,736
116,145
121,055
103,467
116,429
121,427
122,717
139,101
143,068
146,761
152,718
136,303
131,394
137,595
139,498
139,607
144,444
152,261
158,656
144,003
130,302
148,792
152,870
151,266
175,925
184,903
238,931
222,192
203,153
206,916
213,485
235,179
244,762
254,186
252,393
243,068
243,765
226,852
219,965
248,548
244,045
244,045248,548219,965226,852243,765243,068252,393254,186244,762235,179213,485206,916203,153222,192238,931184,903175,925151,266152,870148,792130,302144,003158,656152,261144,444139,607139,498137,595131,394136,303152,718146,761143,068139,101122,717121,427116,429103,467121,055116,14545,73644,64452,07755,68252,96136,33136,75839,78339,61441,38347,55846,79743,500
       Other Current Assets 
46,371
45,640
40,805
37,098
42,214
44,316
49,483
38,978
41,088
41,658
45,290
43,907
43,276
120,728
119,645
107,369
99,016
-435
102,992
112,267
1,000
1,000
1,000
21,193
176,874
176,676
162,039
6,985
178,065
183,109
179,024
152,533
195,192
174,261
161,848
25,624
185,162
164,533
187,710
1,904
170,559
179,067
188,469
6,519
0
0
0
2,076
0
249,181
244,906
18,191
0
018,191244,906249,18102,0760006,519188,469179,067170,5591,904187,710164,533185,16225,624161,848174,261195,192152,533179,024183,109178,0656,985162,039176,676176,87421,1931,0001,0001,000112,267102,992-43599,016107,369119,645120,72843,27643,90745,29041,65841,08838,97849,48344,31642,21437,09840,80545,64046,371
   > Long-term Assets 
100,887
103,648
102,399
105,410
103,538
109,257
111,192
111,464
113,734
114,151
113,796
115,623
119,686
273,737
277,032
279,100
280,079
280,529
281,034
295,281
307,005
310,915
333,036
348,621
360,028
411,462
439,518
469,048
479,446
479,186
477,739
502,596
507,276
520,606
552,574
598,739
595,598
638,291
642,848
669,335
677,719
674,794
672,347
680,432
676,663
672,805
666,954
668,070
656,726
646,515
627,639
649,947
641,949
641,949649,947627,639646,515656,726668,070666,954672,805676,663680,432672,347674,794677,719669,335642,848638,291595,598598,739552,574520,606507,276502,596477,739479,186479,446469,048439,518411,462360,028348,621333,036310,915307,005295,281281,034280,529280,079279,100277,032273,737119,686115,623113,796114,151113,734111,464111,192109,257103,538105,410102,399103,648100,887
       Property Plant Equipment 
95,167
97,928
96,679
98,940
97,068
98,102
99,692
98,902
101,096
100,859
100,106
101,060
104,600
248,585
250,413
269,290
267,604
269,401
269,231
276,241
286,952
289,205
306,688
321,335
335,231
338,175
360,453
386,182
394,041
401,928
404,264
412,248
416,060
424,708
432,013
441,789
460,174
501,672
521,520
542,525
559,559
564,741
569,238
579,919
581,813
577,724
573,884
582,365
576,114
571,953
557,854
566,286
563,357
563,357566,286557,854571,953576,114582,365573,884577,724581,813579,919569,238564,741559,559542,525521,520501,672460,174441,789432,013424,708416,060412,248404,264401,928394,041386,182360,453338,175335,231321,335306,688289,205286,952276,241269,231269,401267,604269,290250,413248,585104,600101,060100,106100,859101,09698,90299,69298,10297,06898,94096,67997,92895,167
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
3,063
0
0
0
8,810
0
0
0
12,727
0
0
0
16,235
0
0
0
19,403
0
0
0
28,113
29,999
29,263
29,361
35,066
35,530
34,957
34,341
39,524
39,062
38,865
38,729
43,980
47,977
47,811
47,801
38,802
0
37,738
0
44,867
0
044,867037,738038,80247,80147,81147,97743,98038,72938,86539,06239,52434,34134,95735,53035,06629,36129,26329,99928,11300019,40300016,23500012,7270008,8100003,06300000000000
       Long-term Assets Other 
5,720
5,720
5,720
6,470
6,470
11,155
11,500
11,500
11,500
11,500
11,500
11,500
11,500
13,300
13,300
1,000
1,000
1,000
1,000
1,000
1,000
1,000
0
1,200
1,200
45,513
50,913
53,263
55,646
47,759
42,432
53,039
51,590
56,271
80,812
113,347
91,070
93,179
78,761
74,586
0
55,132
49,066
43,201
34,383
35,921
33,841
0
38,056
37,738
25,275
23,825
0
023,82525,27537,73838,056033,84135,92134,38343,20149,06655,132074,58678,76193,17991,070113,34780,81256,27151,59053,03942,43247,75955,64653,26350,91345,5131,2001,20001,0001,0001,0001,0001,0001,0001,00013,30013,30011,50011,50011,50011,50011,50011,50011,50011,1556,4706,4705,7205,7205,720
> Total Liabilities 
30,629
35,008
26,174
27,527
26,606
25,775
36,910
23,003
34,797
38,496
38,539
28,847
34,420
351,687
212,347
183,728
184,863
185,683
186,007
206,947
230,175
226,466
237,285
225,375
254,398
316,669
335,052
355,337
377,828
406,994
399,126
390,051
418,454
423,391
402,836
414,611
467,172
482,957
566,849
540,127
568,508
566,271
572,703
566,697
573,233
574,889
708,982
658,012
631,591
649,759
656,884
667,846
690,273
690,273667,846656,884649,759631,591658,012708,982574,889573,233566,697572,703566,271568,508540,127566,849482,957467,172414,611402,836423,391418,454390,051399,126406,994377,828355,337335,052316,669254,398225,375237,285226,466230,175206,947186,007185,683184,863183,728212,347351,68734,42028,84738,53938,49634,79723,00336,91025,77526,60627,52726,17435,00830,629
   > Total Current Liabilities 
25,477
29,856
21,022
21,868
21,198
20,558
31,742
18,554
31,201
34,970
33,901
23,347
28,921
230,029
90,638
74,712
75,820
77,117
87,067
103,156
128,266
134,644
140,244
121,659
149,834
188,149
186,213
222,445
244,949
265,496
248,158
239,442
263,741
266,381
182,965
150,321
198,873
196,426
253,798
230,309
240,686
240,187
258,126
264,591
277,757
290,407
333,065
166,728
141,857
160,264
167,561
177,432
198,330
198,330177,432167,561160,264141,857166,728333,065290,407277,757264,591258,126240,187240,686230,309253,798196,426198,873150,321182,965266,381263,741239,442248,158265,496244,949222,445186,213188,149149,834121,659140,244134,644128,266103,15687,06777,11775,82074,71290,638230,02928,92123,34733,90134,97031,20118,55431,74220,55821,19821,86821,02229,85625,477
       Short-term Debt 
8,332
6,248
4,165
5,341
5,000
0
6,000
0
0
10,000
10,000
0
0
152,780
11,760
18,947
18,252
11,570
25,006
21,498
35,112
32,763
28,301
36,291
59,223
86,033
86,034
121,842
124,338
130,571
124,601
125,441
131,705
131,686
55,486
49,394
63,279
65,451
106,107
103,566
102,097
101,121
117,892
135,081
149,793
162,674
227,154
66,470
51,425
51,146
55,820
47,996
0
047,99655,82051,14651,42566,470227,154162,674149,793135,081117,892101,121102,097103,566106,10765,45163,27949,39455,486131,686131,705125,441124,601130,571124,338121,84286,03486,03359,22336,29128,30132,76335,11221,49825,00611,57018,25218,94711,760152,7800010,00010,000006,00005,0005,3414,1656,2488,332
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
265,000
124,000
123,000
122,000
0
0
0
0
0
0
0
0
0
0
0
0
0
124,601
124,663
131,705
131,686
55,486
48,793
63,279
65,451
106,107
102,925
102,097
101,121
117,892
134,141
149,793
162,674
227,154
65,546
51,425
51,146
55,820
47,996
40,581
40,58147,99655,82051,14651,42565,546227,154162,674149,793134,141117,892101,121102,097102,925106,10765,45163,27948,79355,486131,686131,705124,663124,6010000000000000122,000123,000124,000265,0000000000000000
       Accounts payable 
15,714
22,536
15,045
2,361
14,454
14,222
16,266
6,868
27,491
18,155
18,855
7,579
21,215
64,473
64,382
7,991
53,032
46,295
19,638
26,773
71,262
77,450
87,807
19,055
66,003
75,846
85,306
31,202
119,979
134,560
123,141
34,670
131,223
132,346
125,854
28,150
134,745
127,207
141,291
31,323
129,192
126,156
123,166
51,929
127,484
127,311
105,426
44,526
89,737
107,055
109,822
128,696
156,060
156,060128,696109,822107,05589,73744,526105,426127,311127,48451,929123,166126,156129,19231,323141,291127,207134,74528,150125,854132,346131,22334,670123,141134,560119,97931,20285,30675,84666,00319,05587,80777,45071,26226,77319,63846,29553,0327,99164,38264,47321,2157,57918,85518,15527,4916,86816,26614,22214,4542,36115,04522,53615,714
       Other Current Liabilities 
1,431
1,072
1,812
14,120
1,036
5,272
8,274
10,291
721
3,382
2,994
14,045
4,989
9,318
12,366
47,774
3,658
19,687
46,054
54,885
21,892
24,431
24,136
65,095
23,550
25,376
13,564
69,080
632
365
416
78,679
813
2,349
1,625
72,033
849
3,768
6,400
89,362
9,397
12,910
17,068
76,414
480
422
485
55,365
695
2,063
0
0
0
0002,06369555,36548542248076,41417,06812,9109,39789,3626,4003,76884972,0331,6252,34981378,67941636563269,08013,56425,37623,55065,09524,13624,43121,89254,88546,05419,6873,65847,77412,3669,3184,98914,0452,9943,38272110,2918,2745,2721,03614,1201,8121,0721,431
   > Long-term Liabilities 
5,152
5,152
5,152
5,659
5,408
5,217
5,168
4,449
3,596
3,526
4,638
5,500
5,499
121,658
121,709
109,016
109,043
108,566
98,940
103,791
101,909
91,822
97,041
103,716
104,564
128,520
148,839
132,892
132,879
141,498
150,968
150,609
154,713
157,010
219,871
264,290
268,299
286,531
313,051
309,818
327,822
326,084
314,577
302,106
295,476
284,482
375,917
491,284
489,734
489,495
489,323
490,414
491,943
491,943490,414489,323489,495489,734491,284375,917284,482295,476302,106314,577326,084327,822309,818313,051286,531268,299264,290219,871157,010154,713150,609150,968141,498132,879132,892148,839128,520104,564103,71697,04191,822101,909103,79198,940108,566109,043109,016121,709121,6585,4995,5004,6383,5263,5964,4495,1685,2175,4085,6595,1525,1525,152
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
208,410
253,281
257,254
275,643
299,797
297,797
316,703
315,374
308,069
294,601
283,996
272,275
362,677
0
0
0
0
0
0
000000362,677272,275283,996294,601308,069315,374316,703297,797299,797275,643257,254253,281208,4100000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,664
5,952
0
9,928
0
0
0
0
0
0
0
00000009,92805,9524,664000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
8,000
9,000
7,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000007,0009,0008,0000000000000000
> Total Stockholder Equity
171,153
162,923
169,365
170,503
177,203
187,892
180,103
182,649
191,014
179,800
188,483
193,630
204,763
190,243
448,182
449,718
457,561
446,721
453,062
454,516
464,382
462,575
473,980
479,865
490,647
486,275
500,076
481,041
498,094
503,732
508,416
529,750
541,042
583,942
594,421
643,821
638,783
613,843
612,336
624,004
635,471
638,106
643,983
655,222
668,841
673,903
674,520
687,123
681,664
693,951
696,049
709,152
711,752
711,752709,152696,049693,951681,664687,123674,520673,903668,841655,222643,983638,106635,471624,004612,336613,843638,783643,821594,421583,942541,042529,750508,416503,732498,094481,041500,076486,275490,647479,865473,980462,575464,382454,516453,062446,721457,561449,718448,182190,243204,763193,630188,483179,800191,014182,649180,103187,892177,203170,503169,365162,923171,153
   Common Stock
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
69,739
139,478
139,478
139,478
139,478
139,478
139,478
139,478
139,478
139,478
333,684
333,684
333,684
347,188
347,188
347,188
347,188
369,059
374,404
374,404
374,404
404,922
404,922
404,922
405,857
405,857
405,856
405,856
419,367
419,367
419,367
419,367
432,466
432,466
432,466
432,466
432,466
432,466
432,466
0
0432,466432,466432,466432,466432,466432,466432,466419,367419,367419,367419,367405,856405,856405,857405,857404,922404,922404,922374,404374,404374,404369,059347,188347,188347,188347,188333,684333,684333,684139,478139,478139,478139,478139,478139,478139,478139,478139,47869,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,73969,739
   Retained Earnings 
102,992
94,762
87,484
88,622
95,322
106,011
98,222
100,768
109,133
97,919
106,602
111,749
120,718
106,198
114,500
116,757
124,585
113,183
119,409
121,266
130,830
129,313
140,440
145,596
156,243
166,582
152,686
161,075
175,411
189,308
177,746
182,946
196,507
227,611
203,989
220,182
237,796
210,824
224,253
239,972
260,263
259,622
271,209
288,370
311,003
306,402
310,563
319,065
317,027
333,716
339,693
354,776
361,177
361,177354,776339,693333,716317,027319,065310,563306,402311,003288,370271,209259,622260,263239,972224,253210,824237,796220,182203,989227,611196,507182,946177,746189,308175,411161,075152,686166,582156,243145,596140,440129,313130,830121,266119,409113,183124,585116,757114,500106,198120,718111,749106,60297,919109,133100,76898,222106,01195,32288,62287,48494,762102,992
   Capital Surplus 00000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
-1,578
-1,578
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
12,142
14,306
14,306
194,204
193,483
193,498
194,060
194,205
194,204
194,205
194,205
194,205
585
720
-13,991
202
-27,222
-24,505
-32,764
-38,389
-27,600
-29,869
-18,073
-14,490
18,717
-3,935
-2,838
-17,774
-21,824
-30,648
-40,883
-46,593
-52,515
-61,529
-64,965
-68,509
-64,408
-67,829
-72,231
-76,110
-78,090
0
0-78,090-76,110-72,231-67,829-64,408-68,509-64,965-61,529-52,515-46,593-40,883-30,648-21,824-17,774-2,838-3,93518,717-14,490-18,073-29,869-27,600-38,389-32,764-24,505-27,222202-13,991720585194,205194,205194,205194,204194,205194,060193,498193,483194,20414,30614,30612,14212,14212,14212,14212,14212,14212,14212,14212,14212,142-1,578-1,578



6.3. Balance Sheets

Currency in MYR. All numbers in thousands.




6.4. Cash Flows

Currency in MYR. All numbers in thousands.




6.5. Income Statements

Currency in MYR. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in MYR. All numbers in thousands.

Gross Profit (+$)
totalRevenue813,695
Cost of Revenue-512,157
Gross Profit301,538301,538
 
Operating Income (+$)
Gross Profit301,538
Operating Expense-200,887
Operating Income100,651100,651
 
Operating Expense (+$)
Research Development0
Selling General Administrative81,706
Selling And Marketing Expenses118,878
Operating Expense200,887200,584
 
Net Interest Income (+$)
Interest Income5,965
Interest Expense-26,592
Other Finance Cost-0
Net Interest Income-20,627
 
Pretax Income (+$)
Operating Income100,651
Net Interest Income-20,627
Other Non-Operating Income Expenses0
Income Before Tax (EBT)80,024121,278
EBIT - interestExpense = 80,024
80,024
89,237
Interest Expense26,592
Earnings Before Interest and Taxes (EBIT)106,616106,616
Earnings Before Interest and Taxes (EBITDA)152,008
 
After tax Income (+$)
Income Before Tax80,024
Tax Provision-17,379
Net Income From Continuing Ops62,64562,645
Net Income62,645
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses713,044
Total Other Income/Expenses Net-20,62720,627
 

Technical Analysis of Duopharma Biotech Bhd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Duopharma Biotech Bhd. The general trend of Duopharma Biotech Bhd is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Duopharma Biotech Bhd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Duopharma Biotech Bhd Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Duopharma Biotech Bhd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 1.39 < 1.4254535714286 < 1.46.

The bearish price targets are: 1.3 > 1.3 > 1.3.

Know someone who trades $7148? Share this with them.👇

Duopharma Biotech Bhd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Duopharma Biotech Bhd. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Duopharma Biotech Bhd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Duopharma Biotech Bhd. The current macd is 0.01135565.

The long score for the Moving Average Convergence/Divergence (MACD) is 2/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 0/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Duopharma Biotech Bhd price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Duopharma Biotech Bhd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Duopharma Biotech Bhd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Duopharma Biotech Bhd Daily Moving Average Convergence/Divergence (MACD) ChartDuopharma Biotech Bhd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Duopharma Biotech Bhd. The current adx is 32.14.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Duopharma Biotech Bhd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Duopharma Biotech Bhd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Duopharma Biotech Bhd. The current sar is 1.39914752.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Duopharma Biotech Bhd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Duopharma Biotech Bhd. The current rsi is 55.61. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Duopharma Biotech Bhd Daily Relative Strength Index (RSI) ChartDuopharma Biotech Bhd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Duopharma Biotech Bhd. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Duopharma Biotech Bhd price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Duopharma Biotech Bhd Daily Stochastic Oscillator ChartDuopharma Biotech Bhd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Duopharma Biotech Bhd. The current cci is 17.11.

Duopharma Biotech Bhd Daily Commodity Channel Index (CCI) ChartDuopharma Biotech Bhd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Duopharma Biotech Bhd. The current cmo is 10.45.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Duopharma Biotech Bhd Daily Chande Momentum Oscillator (CMO) ChartDuopharma Biotech Bhd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Duopharma Biotech Bhd. The current willr is -22.22222222.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Duopharma Biotech Bhd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Duopharma Biotech Bhd Daily Williams %R ChartDuopharma Biotech Bhd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Duopharma Biotech Bhd.

Duopharma Biotech Bhd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Duopharma Biotech Bhd. The current atr is 0.03755165.

Duopharma Biotech Bhd Daily Average True Range (ATR) ChartDuopharma Biotech Bhd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Duopharma Biotech Bhd. The current obv is -28,984,000.

Duopharma Biotech Bhd Daily On-Balance Volume (OBV) ChartDuopharma Biotech Bhd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Duopharma Biotech Bhd. The current mfi is 50.26.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Duopharma Biotech Bhd Daily Money Flow Index (MFI) ChartDuopharma Biotech Bhd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Duopharma Biotech Bhd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-18STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-02-19STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-24CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-04ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-17CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-25CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-04-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-25STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-29STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-05-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-08STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-05-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-16STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-19MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-21RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-05-22SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-05-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-28RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-05-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-05-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-06-03STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-05RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-06-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-06-20STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-23STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-07-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-07-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Duopharma Biotech Bhd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Duopharma Biotech Bhd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.609
Ma 20Greater thanMa 501.357
Ma 50Greater thanMa 1001.310
Ma 100Greater thanMa 2001.254
OpenGreater thanClose1.360
Total4/5 (80.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Duopharma Biotech Bhd with someone you think should read this too:
  • Are you bullish or bearish on Duopharma Biotech Bhd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Duopharma Biotech Bhd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Duopharma Biotech Bhd

I send you an email if I find something interesting about Duopharma Biotech Bhd.


Comments

How you think about this?

Leave a comment

Stay informed about Duopharma Biotech Bhd.

Receive notifications about Duopharma Biotech Bhd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.